In early June of last year, HHS announced new laboratory data reporting guidance for COVID-19, citing LOINC In Vitro Diagnostic (LIVD) as the authoritative source of coding for COVID-19 testing. With the number of daily COVID-19 tests continuing to go up in the United States, Dr. Greg Pappas, Associate Director for National Device Surveillance, Center for Devices and Radiological Health, Food & Drug Administration discusses how the LIVD catalog improved public health reporting for COVID-19 test results.
About Greg Pappas
As the Associate Director for National Device Surveillance at FDA, Dr. Pappas has played a key role in the establishment of several FDA initiatives, including the Biologics Effectiveness and Safety System (BEST) and the National Evaluation System for health Technology (NEST). Throughout his career, he has developed innovative partnerships with a broad set of stakeholders including other government agencies, industry, researchers, patient groups, and clinical specialty societies.
